Immune pathway through endometriosis to ovarian cancer

doi:10.5306/wjco.v15.i4.496

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1280)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

HTML

724

Figures (1-5)

Sum=850

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

101

Download

178

Sum=279

Publishing Process of This Article

Item

Count

Browse

Download

Sum=106

Apr 24, 2024 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Apr 24, 2024; 15(4): 496-522
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.496

Full Size Figure Download Figure

Figure 3 Some of the current immunotherapy approaches of treatment to ovarian cancer. Anti-CTLA-4: Cytotoxic T-Lymphocyte Associated Protein 4 Antibody; Anti-PD1: Programmed Cell death Protein 1 Antibody; Anti PD-L1: Programmed Death-ligand 1 Antibody; CAR-T cells: Chimeric Antigen Receptor-T cells; PARP: Poly Adenosine Diphosphate-Ribose Polymerase; PD-1: Programmed Cell death Protein 1; PD-L1: Programmed Death-ligand 1.

Citation: Calmon MS, Lemos FFB, Silva Luz M, Rocha Pinheiro SL, de Oliveira Silva LG, Correa Santos GL, Rocha GR, Freire de Melo F. Immune pathway through endometriosis to ovarian cancer. World J Clin Oncol 2024; 15(4): 496-522
URL: https://www.wjgnet.com/2218-4333/full/v15/i4/496.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i4.496